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Plasma,  dextran,  and other preparations,  although effective as plasma expanders, 
cannot carry oxygen and therefore are not as useful as whole blood for management of 
acute hemorrhage. Blood, on the other hand, has a limited storage time and must be 
typed  and  cross-matched prior  to use.  Hemoglobin in  solution  has  several  unique 
properties which could be desirable for treating hemorrhagic shock. In addition to its 
osmotic activity  (tool wt 68,000),  hemoglobin can  transport  and  exchange  oxygen 
and  has  the  advantage  of not requiring  typing or cross-matching  (1).  Despite  its 
potential, the use of hemoglobin solutions has not progressed past the animal experi- 
mentation  stage because of reports  of renal  damage and methemoglobin formation 
following its administration (2--4). 
Recent studies strongly suggest that disseminated  intravascular  coagulation may 
play an important role in the pathogenesis of renal damage seen in shock, intravascu- 
lar hemolysis, and other situations  (5-8). It has also been dearly demonstrated that 
hemolyzed erythrocytes can initiate blood coagulation (9, 10) and that this coagulant 
activity is confined to erythrocyte stroma (11).  With these observations in mind, it 
may be postulated  that renal damage, following administration  of hemoglobin solu- 
tion, could be due to coagulant activity of red cell stromal contaminants. A stromal- 
free hemoglobin solution would therefore not have deleterious effects on renal function. 
It is the purpose of this report to describe a method for preparation ot large quan- 
tities of a hemoglobin solution which is rdativdy free of stromal particles or lipid and 
has no demonstrable coagulant activity. We also wish to report results of acute and 
chronic experiments  which  show  distribution,  excretion,  oxygen-carrying capacity, 
and effect on renal function of this solution when it is administered to healthy mongrel 
dogs. 
Methods and Materials 
Preparation of Hemoglobin Sobut/on.--Erythroeytes  were separated from outdated,  human 
whole blood and washed three times with 1.6% saline. The washed cells were lysed by adding 
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4 vol of 5 ideal milliosmolar phosphate buffer, pH 7.4 (12), to 1 vol of packed cells; gentle, but 
thorough mixing was effected by repeated inversion of vessel. After standing 30-60 min, the 
mixture was centrifuged at 16,000 g for 90 rain at 5°C. Supematant solution was removed and 
recentrifuged at 35,000 g in a continuous flow centrifuge at a rate of 5.0 ml/min. Supernatant 
was then filtered through a sterile 0.2/~ millipore filter. 
To increase concentration of hemoglobin and  adjust  electrolytes, solution was dialyzed, 
under pressure, against a  standard kidney dialyzing fluid,  1 employing a  Kolff twin coil arti- 
ficial kidney.  Careful  aseptic  technique was  used  throughout.  Sodium,  potassium,  hemo- 
globin, and  methemoglobin concentrations of each batch were determined and cultures for 
bacteria were obtained prior to storage at 5°C in sterile transfusion bottles. 
Experimental Procedure.--In vivo experiments were performed on healthy mongrel dogs 
anesthetized with intravenous sodium pentobarbital. Urinary bladder was catheterized with an 
indwelling Foley-type catheter.  Blood pressure and pulse were monitored from eannulated 
femoral artery  connected  to  a  Sanborn  pressure  transducer  with carrier preamplifier and 
recorder. The femoral vein was also cannulated with a  polyethylene catheter threaded into 
inferior vena cava. (This catheter was also employed for phlebotomy, infusion of hemoglobin 
solution, and to obtain samples for coagulation tests and chemical determinations.) 
Arterial samples were obtained by connecting an adapter bearing a polyethylene catheter 
to an arm of the three-way stop cock which connected femoral artery catheter to pressure 
transducer.  By directing channel of arterial flow through stop cock, blood samples could be 
collected under oil without hemolysis. 
Samples of blood were collected prior to phlebotomy (control) and 5, 30, 60,  120, 180, and 
240 min after hemoglobin infusion. In collecting all samples, the first 5-10 ml of blood was 
discarded and extreme care was taken to avoid hemolysis. Intake of intravenous fluids and 
urinary  output  were determined.  Aliquots of urine were collected for hemoglobin content 
simultaneously with plasma samples. 
Via the femoral vein catheter, 20--47 ml per kg of blood was removed in 2-13 (mean 5.4) 
rain. Immediately following phlebotomy, the animal was infused  in 4-24 (mean  13.0) rain 
with the same volume of hemoglobin solution. After specimens of urine and blood were ob- 
tained as indicated, the experiments were terminated. The animals were sacrificed immediately 
and sample sections obtained from lungs, liver, spleen, and kidneys. These specimens were 
placed in  10%  formalin and  prepared  for microscopic examination  in usual  manner.  The 
remainder of these organs were frozen for future determination of free and red cell hemo- 
globin. 
Prior to phlebotomy and 4 hr after hemoglobin infusion, plasma volume was determined 
with mI-tagged albumin. In addition, 15 rain prior to termination of experiment, 69Fe-tagged 
red cells, obtained from a donor dog,  2 were administered intravenously to permit determina- 
tion of tissue hemoglobin (see determination of free hemoglobin and red cell hemoglobin in 
tissues). 
Coagulation St~dles.--As previously indicated, extreme care was taken to avoid hemolysis 
of samples obtained for coagulation studies as well as other determinations The first syringe 
with 3-5 ml of blood was discarded and the actual sample collected in a  second disposable 
plastic syringe. 
Clotting time was performed by the Lee and  White method  (13),  except that  plastic, 
rather than glass test tubes, were employed. To insure that clotting time would be significantly 
shortened by activation of the initial phase of blood coagulation, care was taken to avoid con- 
tact of plasma with any surface other than plastic (intact plasma). 
1 g/100 L  =  NaCl--570, NaHCO3  --  300, KU  --  30, CaCl~14, and MgC12.6HsO  -- 15. 
300-500/~c of 59FeSO4  administered intravenously, 10 days later 40 ml blood was collected 
in ACD solution and red cell washed three times with normal saline. RABINER~  HELBERT~ LOPAS~ AND ]~RIEDMAN  1129 
Prothrombin activity was performed by the Ware and StragneU method  (14), factor V 
assays by the method of Biggs and Macfarlane (15), fibrinogen by a  modification  of  the 
Cullen and VanSlyke method (16), and factor VIII (AHG) assay by the method of Rapaport, 
Schittman, Patch, and Ware (17) with the following modifications: 
1.  Citric acid was not added to the anticoagulant. 
2.  Soy bean phosphatide (Inosithin-Associated Concentrates,  Woodside,  N.Y.)  was  em- 
ployed instead of chloroform extract of brain. 
3.  Celite Llohns-Manville falter cell) was employed instead of Kaolin. 
4.  Imidasole buffer-0.04 M pH 7.35 was employed instead of verona1 buffer. 
5.  Factor VIII-deficient plasma, obtained from a  patient with classical hemophilia, was 
employed as substrate instead of factor X.I-deficient plasma. 
To study the e~ect of hemoglobin solution on clotting of intact plasma either 0.1  ml of 
hemoglobin solution or imidazole buffer (control) was added to 0.4 ml of normal intact plasma 
in a  12 X  75 ml plastic tube (Falcon 2003). The test tube was gently mixed, placed in a 370C 
water bath, and 0.1 ml of 0.1 ~  calcium chloride was added. A stopwatch was started simul- 
taneously with the addition of calcium chloride. At l-rain intervals the test tube was picked 
up and tilted very gently to note clot formation as in Lee White dotting time. Throughout the 
day repreated control dotting times were performed to insure intact state of test plasma. 
Determination of Free Hemoglobin  and Red Cell Hemoglobin  in Tissues.-- 
General principles: Total tissue hemoglobin was determined colorimetricaUy as acid hematin 
in organ homogenates (18). The portion of total tissue hemoglobin derived from red cells in 
the vascular space was calculated on the basis of isotopic dilution of 5°Fe-labeled red cells 
injected just before sacrifice and the gamma counting rate of tissue homogenates and whole 
blood. The free hemoglobin of the tissues is equal to total tissue hemoglobin minus the red 
call hemoglobin. 
Separation of tissues for hemoglobin analysis:  15 rain after injection of labeled red celis, a 
sample of venous blood was obtained and the animal was sacrificed. Major vessels of organs 
were ligated and whole organs were removed and frozen overnight at --40°C. 5-6 g aliquots 
were taken from each frozen organ and homogenized with 35-45 ml of distilled water in a 
micro-Waxing Blendor, until a fine suspension was obtained. 
Determination of total tissue hemoglobin: 5 ml of tissue homogenate was brought to 25 ml in a 
volumetric flask with acid acetone, the latter consisting of two parts 2.5%  HC1 and eight 
parts acetone (w/v). The suspension was shaken, transferred to a  stoppered centrifuge tube, 
and centrifuged at 4°C at  11,000 g for 30 rain. The transmission of supernatant was deter- 
mined at 635/~ in a Beckman DB spectrophotometer. The hemoglobin content of the sample 
was calculated from a  standard hematin curve prepared, as above, from whole blood with a 
known hemoglobin content. The hemoglobin content per gram of tissue is then calculated. 
Determination of red cell hemoglobin content  of tissue:  1 ml of the whole blood sample ob- 
tained just prior to sacrifice was hemolyzed by addition of 2 ml of distilled water, and 59Fe 
activity was determined in a well-type scintillation detector (Packard Auto Gamma Spectrom- 
eter). The relationship between the hemoglobin concentration of peripheral blood and  the 
radioactivity of 5SFe was then determined. A  3  ml aliquot of each organ homogenate was 
counted in a  similar manner. The contribution of red cell hemoglobin to total tissue hemo- 
globin was calculated and subtracted from total tissue hemoglobin. 
Miscellaneous determinations:  Plasma hemoglobin was performed by the Crosby method 
(19) and methemoglobin by the Evelyn and Malloy method (20). The oxygen content of blood 
and plasma was determined by the Peters and Van Slyke method (21)  employing a Van Slyke 
manometric apparatus (Thomas Magnematic model). Standard methods were employed for 
determination of sodium, potassium, whole blood hematocrit, and hemoglobin, the latter as 
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Renal Function Studies.--A series of experiments were performed to determine the effect of 
infusion of the described hemoglobin preparation on renal function. Clearances of urea, crcat- 
inine, and para-minohippuric acid (P.A.H.) were measured by methods as described by H. 
Smith  (23), on anesthetized mongrel dogs. Venous and arterial  catheters were inserted for 
infusion, sampling, and to monitor vital signs. 
Prior to the first clearance period each animal was infused with normal saline at a dose of 
75 ml/k over a 4S-rain period. A series of four consecutive 30-rain clearances were then per- 
formed (control periods). Between 25-28 ml/k of blood was then removed by gravity into 
plastic bags, the amount determined by the changes in the weight of bags. 
Immediately  after  phlebotomy  either  the withdrawn  blood was reinfused (whole blood 
animals) or an equal amount of hemoglobin solution was administered (hemoglobin animals), 
over a 30 rain period. Each group consisted of five animals and was comparable. All infusions of 
saline, blood, hemoglobin, creatinine, and P.A.H. were performed via a Harvard pump at 
calculated rates. Following  a 45 rain rest period, four additional, consecutive 30-rain clearances 
TABLE I 
Effect of Filter Pore Size on Coagulant Acidity of Hemolysate 
Unfiltered 
Filtered 
1.2# 
0.45/z 
0.2/z 
0.1/z 
Control 
Clotting time  Prothrombin  consumption 
rain 
7 
7 
9 
13 
25 
14 
112.0 
49.5 
64.5 
35.8 
30.4 
28.2 
were performed (acute periods). Animals were then returned to their cages. 2-5 days later two 
additional periods, each consisting of four consecutive 30-rain clearances separated by a 1 hr 
rest period (chronic periods) were performed. The animals were then sacrificed by injection of 
sodium pentobarbitol  and immediately autopsied.  Following careful gross examination of 
kidneys, multiple specimens were fixed in formalin and histological sections were prepared in 
usual manner. 
RESULTS 
In  V2ro  Properties  of  Hemoglobin  Solutions.--Since  hemolysate  has  the 
ability  to  shorten  clotting  time  and  improve  prothrombin consumption of 
intact plasma (22), these parameters were employed to test in vitro coagulant 
activity of hemoglobin preparations. It was found that significant coagulant 
activity persisted after centrifugation of hemolyzed erythrocytes. This coagu- 
lant activity was removed by filtration (Table I). The unfiltered preparation 
shortened  clotting  time  and  improved  prothrombin  consumtpion of  intact 
plasma. This coagulant activity was not significantly  reduced until the prepara- 
tion was passed through 0.1-0.2 #  millipore filters. RABINER,  HELBERT,  LOPAS,  AND  FRIEDMAN  1131 
Coagulation studies were performed employing a hemoglobin  solution  pre- 
pared in the manner described  by Hamilton et at.  (1). Although free of par- 
ticulate matter, this preparation was found to be heavily contaminated with 
stromal lipid.  When added, undiluted, to intact plasma,  it acted as an anti- 
coagulant and the resultant mixture could not be dotted. However, by diluting 
this preparation with saline,  coagulant activity could  be  demonstrated and 
significant  shortening of dotting time was found with dilutions as high as 
1:250  (Table  II).  After  this  hemoglobin  preparation  was  extracted  with 
chloroform,  it no longer had coagulant activity and furthermore, coagulant 
lipid  could  be  recovered  from  the  chloroform  by  evaporation.  Chloroform 
extractions of coagulant-free  hemoglobin  solutions,  which  were  prepared  as 
described in this report, yielded little or no lipid. 
TABLE II 
Effect of the Addition  of Hemoglobin Solutions on Clotting Time of Normal 
Plasma in Plastic Test Tubes 
Preparation added 
Present 
P. B. Hamilton,  et al. 
No. of 
determinations 
Clotting time 
deviation from 
control 
-0.6 
--11.2 
SE 
0.95 
1.85 
Following reverse  dialysis of our hemoglobin solution,  the average concen- 
tration of hemoglobin  was  7.0  g/100 ml, sodium  126 meq/L, potassium 4.4 
meq/L, and methomoglobin 0.4 g/100 ml. 
There  was  no  demonstrable  methemoglobin  formation when  hemoglobin 
solution was stored at 5°C in sterile bottles for 8 months. In fact, methemo- 
globin formation did not occur  when pure  oxygen was  bubbled through an 
aliquot of this solution  for 12  hr. 
Oncotic Activity  of Hemoglobin  Preparation.--In  vivo experiments  were per- 
formed on eight anesthetized dogs. Following phlebotomy, there was the ex- 
pected rise in pulse and fall in blood pressure, commensurate with the amount 
of blood removed.  Infusion of hemoglobin solution  in each instance promptly 
restored blood pressure  and pulse rate to prephlebotomy levels and this was 
maintained throughout the experimental period. 
One can estimate the osmotic effect of infused hemoglobin solution  by cal- 
culating, from intake and  output measurements,  the  theoretical change  in 
plasma volume that should have occurred during the experiment and comparing 
this value with the true change  in plasma volume,  as determined with 1811- 
labeled albumin.  For these calculations  we estimated the per cent of infused 
hemoglobin  solution remaining  in the plasma at the termination of the ex- 50 
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periment  (4  hr).  The  actual  final plasma volume  (mI-tagged albumin)  was 
higher than the calculated final plasma volume in six of the seven experiments. 
This difference varied between  16-49  rnl/k  and  was directly proportional to 
the amount of hemoglobin per kilo infused. 
This is illustrated in Fig.  1 which is a  scatter diagram illustrating the rela- 
tionship between the volume  of hemoglobin solution infused per kilo and the 
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FIG. 1. Relationship between volume of hemoglobin  infused and increase in plasma volume. 
The dots represent differences  obtained when final volume of residual infused hemoglobin  was 
calculated from total body distribution data. The X's are differences  when final volume of 
infused hemoglobin was calculated from change in plasma hemoglobin. The solid line is re- 
lated to dots and interrupted line to the X's. 
difference between the actual and  calculated plasma volume change. (The dots 
represent differences obtained when final volume of residual infused hemoglobin 
was calculated from total body  distribution data while the x's are values ob- 
tained when this was calculated from change in plasma hemoglobin. The solid 
line is related to the dots and the interrupted line to the x's.) Both lines are 
constructed  by  the  method  of  least  squares,  and  the  correlation  coefficient 
of each is 0.8. Since this is significant between 5 and 1%, it can be assumed that 
the two variables are functionally related. 
Oxygen Content and Arterial Value (A-V) Difference of Infused Hemoglobin.- 
The mean oxygen content of infused hemoglobin, as determined from arterial RABINER,  HELBERT,  LOPAS,  AND  FRIEDMAN  1133 
plasma samples, was 3.60 q- 0.72 (SD) VOI/100 ml. The mean predicted oxygen- 
carrying capacity, calculated by multiplying the plasma hemoglobin concen- 
tration  by 1.34, is 3.83  4-  0.88  (SD) vol/100 ml.  If we assume 97 % arterial 
hemoglobin saturation,  the mean predicted oxygen content is 3.72.  There  is 
no  significant  difference  between  actual  and  predicted  oxygen  content 
(P >  0.40).  Furthermore,  the individual oxygen values correlated well with 
their  predicted values  (r  =  0.9554,  P  <  0.001)  and  this  relationship  was 
maintained  throughout the experimental period. There  was no demonstrable 
methemoglobin conversion of infused hemoglobin.  Analysis of plasma oxygen 
from venous and  arterial  blood revealed a  consistent,  significant  A-V differ- 
ence (P  <  0.001).  The mean A-V difference  was 13 % of the arterial value. 
These observations indicate that the infused hemoglobin  both transports and 
exchanges  oxygen. 
TABLE III 
Diaribv2ion of Infused ttemoglobin after 4-5 Hr 
Liver 
Spleen 
Kidney 
Plasma 
Urine 
Total recovery 
Per cent of total hemoglobin  infused 
23.4  -4-  7.7 
4.5  :/:  1.0 
10.6  4-  10.7 
40.4  -¢-  8.5 
9.3  ::k  9.7 
88.2  ~  11.9 
Distribution  and  Excrelion  of  Infused  Honoglobin.--The  distribution  of 
free hemoglobin  was determined 4-5 hr after infusion in four animals.  Indicated 
in Table ILl are the mean values, with standard deviations, of the per cent of 
total  infused hemoglobin recovered in organs,  plasma,  and  urine.  The most 
significant  variation occurred in the amount excreted in urine and that recov- 
ered in kidney. 
The disappearance rate of hemoglobin from plasma is illustrated in Fig. 2. 
On the basis of data from eight experiments,  the "half  disappearance  time" 
of our hemoglobin preparation  in the circulating plasma is 4-5 hr.  This dis- 
appearance  curve appears  to be biphasic with an initial  rapid phase ending 
at 1 hr. Also shown is the disappearance of hemoglobin  when infused into two 
animals whose ureters were tied just prior to the experiment.  In these dogs 
the initial  fall in  hemoglobin concentration  is  parallel  to  and  approximates 
the  rapid  phase  of normal  dogs.  The  second phase,  however,  is  more pro- 
longed.  Although this prolongation falls within the standard deviation of the 
line obtained with  normal  dogs,  the straight  line  relationship  of the values 1134  STROMA-FREE  HEMOGLOBIN  SOLUTION 
speaks  strongly against random distribution.  Of interest is the fact that  at 
4 hr, the mean plasma hemoglobin of ureter-tied dogs is 9 % higher than that 
obtained with normal dogs. This difference is in agreement with the mean value 
of 9.3 % of the total infused hemoglobin excreted in the urine of normal dogs 
(Table IV). 
Effect  of Hemoglobin Infusion  on Activation  of  Coagulation Mechanism.-- 
Following intravascular coagulation, there is a  rapid fall in factors V, VIII, 
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FIo. 2. Plasma clearance of infused  hemoglobin. 
and fibrinogen. Since these factors do not effect the prothrombin activity test 
(14),  these factors were therefore assayed at intervals and the fluctuation of 
V,  VIII,  and  fibrinogen was  compared  to  changes  in  prothrombin  activity 
following infusion of hemoglobin solution  (Table  IV).  This  comparison was 
felt to be important since changes in prothrombin activity should reflect endoge- 
nous or exogenous dilution. An analysis of this data is presented in Table IV. 
It can be seen that the difference between prothrombin activity and factors 
V, VIII, and fibrinogen 4 hr after hemoglobin infusion is small and cannot be 
considered either clinically or statistically significant. 
Effect of Hemoglobin Infusion on Renal Function.--Clearance  of urea, creati- RABIIVER,  HELBERT,  LOPAS,  AND  FRIEDMAN  1135 
nine, and P.A.H. was measured in a series of five hemoglobin-infused dogs and 
the results compared to an identical series of whole blood-infused dogs. Both 
acute effects, 45 min postinfusion, and chronic effects, 2-5  days postinfusion, 
were determined. The analysis of data was carried out by the following steps: 
1. The mean clearance for the four 30-rain values during the control period 
for each dog was computed and used as the resting value for that dog. 
2. The per cent change from this resting value for each subsequent  clearance 
for a given dog was then determined (four acute clearances and  eight chronic 
clearances). 
3. An analysis of variance of these per cent changes was used to determine 
the relative components of variation,  among dogs and among ~-hr  periods. 
TABLE IV 
Comparison of Prothrombin Adi~ri~y (Ware and StragndO  and other Coagulation Factors 4 Hr 
after Infusion of Hemoglobin 
Coagulation factors 
VIII 
V 
Fibrinogen 
Difference between prothrombin activity (%) 
and activity of c~gulation factors (%) 
Mean* 
--4.25 
-t-4.625 
-t-6.25 
SZ of Mean 
5.52 
6.85 
3.85 
--0.95 
-4-0.68 
-t-1.62 
*N-8. 
~: Critical value @ 0.05 =  2.306. 
The principal component  of variation was  found  to be the  variation  among 
dogs. 
4.  For each dogs the mean per cent change for all ~-hourly observations 
(four acute or eight chronic observations) was computed. 
5.  The mean per cent change and its standard  error were then computed 
for the five dogs,  in each measure  of clearance, for both treatments  (whole 
blood and hemoglobin), for acute and for chronic effects (Table V). None of 
these per cent changes was  significantly different from 0. 
6.  The  difference between  whole  blood  and  hemoglobin  effects was  then 
tested by a t test for each clearance measure and for acute or chronic effects. 
In no case was there a significant difference between these two treatments. 
Employing the same analysis for urinary output per minute the mean acute 
change -4-sw for whole blood dogs was +46.1  -4-  29.1% and for hemoglobin 
dogs  3-227.1  -4-  120.8%.  The  mean  chronic  changes  for  whole  blood  and 
hemoglobin dogs were respectively -4-11.1 =t:  23.4 and 110 :t:  97.9%.  T  tests 
of  the  acute  and  chronic means  revealed  no  significant  difference between 
treatments  (P >  0.20 for acute and P  >  0.40 for chronic). 1136  STROMA-FREE  HEMOGLOBIN  SOLUTION 
Examination of histological sections was performed on eight dogs sacrificed 
4 hr; one dog, 2 days; two dogs, 3 days; three dogs, 4 days; three dogs, 5 days; 
and one dog, 6  days after hemoglobin infusion. Special attention was  given 
to tubular changes that might have been related to hemoglobin infusion such 
as  cellular  necrosis  and  degeneration  as  well  as  pigmented  casts  (24,  25). 
All segments of the nephron were carefully examined and no significant changes 
were seen. In two animals, occasional pigmented casts were seen in the distal 
portion of the nephron. The extremely small number of these casts morpho- 
logically excludes  the  possibility of  obstruction  and  significant interference 
with renal function. In addition the lack of cellular degeneration in the same 
tubules would indicate no noxious effect of infused hemoglobin under  condi- 
tions of experiment. 
TABLE V 
Acute effects  Chronic effects 
Clearance  Change*  Change* 
Urea 
Creatinine 
P.A.H. 
Whole blood 
% 
+10.4  A:  6.3 
+17.1  -4-  9.5 
+5.4  ±  14.3 
Hemoglobin 
% 
+5.25  "4- I1.0 
+20.1  "4- 10.1 
+8.0  =l:  12.1 
Com- 
parison of 
means P 
value 
>0.70 
>0.80 
>0.90 
Whole blood 
% 
+11.69  -~-  12.2 
+24.1  "4-  12.6 
+16.8  :i: 10.1 
i  Hemoglobin 
% 
+3.0  -4- 7.6 
+ii.0  -4- 7.2 
+14.7  ±  10.7 
Com- 
parison ot 
means P 
value 
>0.60 
>0.40 
>0.90 
* Mean clearance ml/min/M  2 ±  sE. 
DISCUSSION 
The concept of employing hemoglobin as a  plasma expander  is  not  new. 
Extensive in vitro and in vivo experiments with a variety of preparations  have 
been made  (1-3,  26,  27).  Many  of  these  preparations,  like  ours,  have  been 
found to be stable  and  to combine with oxygen  normally.  These studies  were 
abandoned  mainly  because  of  the  reduction  of  urea  clearance  in  recipient 
animals (2). 
The mechanism of kidney damage following hemoglobin infusion has also 
been  studied.  Some  have  postulated  that  tubular  blockage  by precipitated 
hemoglobin is the primary cause of renal failure  (24,  28-31),  while other oh- 
servers  found either  no  tubular  obstruction  (4,  30)  or  regard  reduction  in 
glomerular filtration plus renal isehemia as primary causes (25, 33, 34). 
Previous  work  in  this  laboratory has  shown  that  infusion of  autologous 
hemolysate into dogs results in production of a  hypercoagulable state which 
can go on to actual intravascular coagulation. In addition we have been able 
to  corroborate  the  observation  that  coagulant activity of hemolyzed blood 
resides in stromal rather  than hemoglobin fraction and to demonstrate that 
stromal particles are cleared by the reticulo-endothelial system (10). RABINER, HELBERT, LOPAS, AND FRIEDMAN  1137 
This work, plus the observations  by others,  of the important role of intra- 
vascular coagulation in pathogenesis of renal damage due to numerous causes, 
suggest the possibility  that the "ischemia" implicated in the pathogenesis  of 
renal damage following hemoglobin infusion may be due to arterial thrombotic 
lesions  resulting from  the  initiation of  coagulation  mechanism  by stromal 
particles.  This concept is supported by the fact that following infusion of our 
stroma-free  hemoglobin  solution  there  was  no  demonstrable  functional  or 
structural effect  on  the kidney. The doses  employed and  the  experimental 
conditions  of previous  investigators varied and for this reason  it is difficult 
to make direct comparisons.  However,  the dose employed and experimental 
animal in the study by Hamilton et al. (2) is comparable  to our study. They 
found a  fall in urea  clearance  which  was demonstrable several  hours  after 
hemoglobin infusion and which lasted as long as 2 wk. Urea clearance was not 
significantly altered in our experiments during these same periods. 
Brandt et al. found a prompt fall in P.A.H. clearance and urinary output 
during infusion of hemoglobin solution to well hydrated humans (33). Although 
his dose was comparable  to ours, he gives no data on duration of renal effect 
following cessation  of hemoglobin injection.  We found no changes in P.A.H. 
clearance  or  urinary output.  Goldberg  also found a  significant  fall in  urine 
flow, creatinine clearance,  and P.A.H. clearance  following administration of 
homologous hemolyzed  red blood  cells to dogs  (31). He found no change  in 
renal blood flow by a  gas diffusion technique using krypton. However,  he in- 
fused his preparation directly into the aorta above  renal arteries,  and used 
a  much smaller  amount of hemoglobin  (~J-~0  of our dose).  Jaenike found 
decrease in inulin clearance and development of a renal lesion following infusion 
of hemoglobin into dehydrated rats (25, 34). However, the dose of hemoglobin 
employed in his experiments  was approximately 25 % of ours and our animals 
were all hydrated prior to the first clearance period. Because of the-differences 
in experimental  design we cannot definitely attribute the results  to differences 
inherent in our hemoglobin preparation. We are presently studying the effect 
of various  other  hemoglobin  preparations in  a  comparable  series  of experi- 
ments. 
The method described  in this paper is designed to prepare  large quantities 
of stromal-free hemoglobin solution from outdated bank blood. To accomplish 
this,  we  were  concerned  not  only with  removing  particulate  matter,  but 
avoiding contamination of hemoglobin solution with stromal lipid. 
By utilizing coagulant activity as a test for presence of stroma, we found that 
to remove all detectable stromal particles,  it was necessary to first centrifuge 
at high speeds  and then pass  the solution  through an 0.2 #  millipore  filter. 
In order to avoid contamination of hemoglobin with nonparticulate stromal 
lipid, a modification of a method designed for the preparation of hemoglobin- 
free ghosts was chosen (12). This method uses, as a hemolyzing agent, a hypo- 1138  STROMA-~REE  HEMOGLOBIN  SOLUTION 
tonic phosphate buffer of controlled osmolarity and pH. When this buffer is 
used essentially all stromal lipid can be recovered in the ghosts. Other workers 
have found that when water was employed for hemolyzing red cells of fresh 
ACD blood, up to 10 % of phospholipid is lost from stroma and that this was 
increased to as much as 30 % when bank blood was employed or if oxalate was 
used as an anticoagulant (35). In reviewing the literature, one finds that hemo- 
globin solutions have been used by many investigators for a variety of experi- 
ments, in addition to those designed to study hemoglobin as a plasma expander 
(1,  2, 26, 27).  Some have investigated the effect of hemoglobin on the kidney 
(2, 4, 24, 25, 28-34),  the anfigenicity of hemoglobin (36-43), hemoglobin and 
iron  metabolism  (44-48),  effect  of  hemolysate  on  blood  coagulation  (22), 
and role of intravascular hemolysis on production of a  hypercoagulable state 
(10).  Water was used to hemolyze erythrocytes in many of these studies (1, 
2, 25, 29, 31, 32, 34, 41, 44-48) while other methods included the use of ultra- 
sonic vibrations  (4,  10),  mechanical trauma  (33),  and freezing then thawing 
(22).  Following hemolysis, efforts to further purify solution also varied. While 
some investigators were content to use the hemolysate without further purifica- 
tion (44)  most felt it necessary to at least centrifuge and decant the super- 
natant. Others purified their preparation by chromatography (40, 42, 43, 48). 
While it is probable that these hemoglobin solutions were perfectly adequate 
for many of the studies in question, it is nevertheless important to realize that 
many of these solutions, by nature of their mode of preparation, were very 
likely contaminated with stromal particles, lipid, or both. This fact should be 
taken  into  consideration when evaluating the  results  of experiments where 
effects attributed to hemoglobin may actually have been caused by stroma. 
We have studied the preparation of Hamilton et al. (1)  which was used as a 
plasma expander and also employed to test effect of hemoglobin on the kidney 
(2, 4). This solution, although free of particulate matter, was heavily contami- 
nated with stromal lipid and  therefore  had  considerable  coagulant activity. 
This is in contrast to the preparation described in this paper which had very 
little demonstrable lipid and no coagulant activity. 
The  amount of hemoglobin infused in  our  experiments was  1.4--3.3 g/k. 
which is far in excess  of the amount employed by other investigators in ex- 
periments designed to study distribution, excretion, and metabolism of hemo- 
globin (45-48). It is accepted by most workers in the field that, in the circula- 
tion,  extracorpuscular  hemoglobin  combines  with  haptoglobin  to  form  a 
molecule which is not filterable by the renal glomerulus and is cleared by the 
reticuloendothelial system. When the level of hemoglobin exceeds the hapto- 
globin-binding capacity, the  unbound  hemoglobin  can  be  excreted  by the 
kidneys. The  level of haptoglobin  and  its  rate  of productila  varies  among 
species  and  can be  altered  by disease  states  or  chronic hemolysis (49-51). 
Anderson et al. administered graded doses of hemoglobin, labeled with ~Cr, 
to dogs and found that the plasma hemoglobin must  exceed  70  rag%  before RABINER~  HELBERT,  LOPAS,  AND  ~RIEDM-AN  1139 
significant amounts appear in urine  (48).  In our experiments, initial plasma 
hemoglobin levels, obtained 5  rain after completion of infusion, varied from 
1.6-4.3  g%.  Assuming  haptoglobin binding  of 70  rag%,  the unbound  (free) 
hemoglobin in  these  experiments varied from 57-83%  of the  total  infused. 
The per  cent  excreted in urine  varied widely,  could not  be correlated with 
either amount of hemoglobin infused or initial plasma  hemoglobin, and was 
always much less than the theoretical per cent of free hemoglobin. Also, the 
per cent of total dose found in liver and spleen was also always greater than 
theoretical  per  cent  of  haptoglobin-bound  hemoglobin.  These  observations 
are in agreement with those of Andersen et al. who also found that the total 
amount of hemoglobin excreted in urine accounted for only a small percentage 
of free hemoglobin. This  suggested  to  them  that  the  major portion  of free 
hemoglobin was cleared from plasma by body tissues (48). Our results are also 
in agreement with the observation made by others that the liver is the principal 
organ involved in hemoglobin clearance  (45,  46). 
Administration of the described hemoglobin preparation to phlebotomized 
dogs  resulted in  a  prompt  restoration of vital signs  which  were maintained 
throughout the  experimental period  (approximately 4  hr).  This,  along with 
autopsy findings, supports the concept that this preparation is nontoxic. We 
cannot at this time claim a beneficial effect of hemoglobin infusion on prognosis 
of hemorrhagic shock. It is our hope that future experiments, employing a well- 
controlled shock model, will demonstrate the effectiveness of this  preparation 
against shock. 
SUMMARY 
The preparation of large quantities of a stable, stroma-free hemoglobin 
solution without coagulant  activity  is described.  Following  infusion  of this 
solution into  phlebotomized dogs, there is no methemoglobin formation, no 
adverse effects  on vital  signs,  and no demonstrable activation  of  blood coagula- 
tion. The hemoglobin maintains  its oxygen-carrying  capacity and liberates 
oxygen into tissues.  Acute and chronic  effects  on renal  function following  in- 
fusion  of this  preparation were also  studied and no effect  on clearance  of urea, 
creatinine,  or P.A.H. could be demonstrated. There was no change in urinary 
output and histological  sections revealed no lesions  attributable to hemo- 
globin toxicity.  It is concluded that a stroma-frce hemoglobin solution  may 
have use as a plasma expander. 
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